कंपनी का अवलोकन
iSpecimen Inc. operates a specialized marketplace designed to supply biospecimens to life science researchers located globally, facilitating connections between medical researchers requiring access to subjects, samples, and data with hospitals and laboratories. This entity functions within the Healthcare sector, specifically categorized under the Diagnostics & Research industry, where it serves as an intermediary platform rather than a direct manufacturer of medical devices or pharmaceuticals. The company's financial scale is characterized by a market capitalization of $3.86M, derived from an annual revenue of $1.93M and a minimal workforce of 7 employees. These valuation figures indicate that the company operates with a very small asset base and limited operational footprint relative to its revenue generation, suggesting a capital-light business model typical of early-stage marketplace or technology-enabled service providers in the diagnostic research space.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $1.93M, yet this revenue generated a net income of $-10,487,532, revealing a highly distorted cost structure where expenses significantly outweighed all income sources. The EBITDA for the period stood at $-8,717,890, further confirming that operational cash generation is currently insufficient to cover the company's total cost of operations. Consequently, the free cash flow was negative at $-2,782,585, which indicates a lack of financial flexibility and an inability to fund capital expenditures or working capital needs without external financing. The gross margin is reported at 1.2%, while the operating margin is -5192.9% and the profit margin is 0.0%, indicating that the company is unable to generate profit from its core business activities and is operating at a substantial loss on every dollar of sales. The balance sheet shows a cash position of $6.88M against total debt of $268,798, but the debt-to-equity ratio is an alarming 8.70, suggesting a highly leveraged capital structure relative to shareholder equity. Despite the high debt-to-equity figure, the current ratio is 1.12, which indicates that the company possesses enough current assets to cover its current liabilities, though the margin of safety is narrow. The return on equity is -327.8% and the return on assets is -59.4%, metrics that reveal that management has not been effective in generating positive returns on the capital invested by shareholders or the assets utilized by the firm.
मूल्यांकन आकलन
The trailing P/E ratio is N/A due to the lack of net income, whereas the forward P/E is listed as -0.16, a metric that is mathematically derived from negative earnings and does not provide a traditional valuation multiple for investors. The price-to-book ratio stands at 0.41, indicating that the market values the company's equity at a fraction of its book value, which often occurs when assets are undervalued or when the business model carries significant intangible risks. Alternative valuation metrics such as the price-to-sales ratio of 2.00 and an EV/EBITDA of 0.32 are being used to assess value in the absence of profitable earnings, suggesting the market is pricing the company based on revenue potential and enterprise value adjustments rather than profitability. The stock has traded between a 52-week high of $3.18 and a 52-week low of $0.13, meaning the current trading price sits significantly below the recent peak, reflecting a substantial decline in market sentiment over the past year. The beta value of 1.98 suggests that the stock price exhibits high volatility, moving nearly twice as much as the broader market index in either direction, which implies a higher risk profile for investors seeking stability.
Growth & Income
Revenue growth year-over-year has contracted sharply by -96.5%, while earnings growth is N/A due to the company reporting a net loss, indicating that the business is currently shrinking rather than expanding its top line. Since the company is not a dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute any portion of its earnings to shareholders, as there are no positive earnings to distribute. This absence of dividends necessitates that the company reinvest any available capital or rely on cash reserves to fund operations and potential future growth initiatives, although current cash burn poses a challenge to this strategy. The overall growth and income profile for iSpecimen Inc. is characterized by significant revenue contraction, negative returns on capital, and a complete absence of dividend income, presenting a high-risk scenario for income-focused or growth-oriented investors.